A new study has found that switching among multiple biosimilar infliximab products was not associated with increased immunogenicity in patients with inflammatory diseases.
A new study has found that switching among multiple biosimilar infliximab products was not associated with increased immunogenicity in patients with inflammatory diseases.
The study, presented at the European League Against Rheumatism European Congress of Rheumatology 2019, was conducted at a single center in France.1
The study’s prospective cohort included 265 patients, 135 of whom had axial spondyloarthritis, 64 of whom had inflammatory bowel disease, 31 of whom had rheumatoid arthritis, 21 of whom had psoriatic arthritis, 8 of whom had uveitis, and 6 of whom had other inflammatory diseases.
These patients were all treated with the reference infliximab, then were switched to a biosimilar and followed for 3 years. Prior to the switch, 29 patients had antidrug antibodies (ADAs).
Later, at year 2, 140 patients were switched to a second biosimilar infliximab, while 26 remained on the first biosimilar and 55 patients switched back to the reference product. Among the 236 patients with no ADAs before the first switch occurred, 20 developed ADAs during the observation period, corresponding to a rate of 3 per 100 patient years. The mean (SD) time to ADA detection was 21.2 (13.7) months.
Kaplan—Meier analysis showed that the number of biosimilars received did not impact development of ADAs. Among the 20 patients who developed new ADAs, 4 were taking the reference product at the time of detection, while 10 had been exposed to the first biosimilar only, and 6 had been exposed to both biosimilars.
No predictive factors, including age, disease state, sex, body mass index, or concomitant drug therapy, were identified for immunogenicity.
The retention rate for biosimilar infliximab was 58% at the end of the observation period, including 131 patients treated with the second biosimilar and 23 patients treated with the first biosimilar.
According to the authors, “immunogenicity does not constitute a barrier to interchangeability between biosimilars infliximab in chronic inflammatory diseases.”
These results are a notable addition to the literature on switching among biosimilars of the same reference drug; switching among multiple products is increasingly common in countries where single-winner tenders for biosimilars are undertaken and in which patients may be asked to transition among products regularly based on the outcome of the tendering process. Increased immunogenicity has been a stated concern among some physicians who question the practice of nonmedical switching among products, and these real-world data may provide reassurance that such switches do not pose a problem with respect to increased immunogenicity.
These results follow those of another study, also conducted in France, in which 21 patients with psoriatic arthritis were switched from one biosimilar infliximab to another, then followed for 6 months.2 In this study, investigators found that the switch between the biosimilars was not associated with a statistically significant change in disease activity or with increased adverse events.
References
1. Lauret A, Moltó A, Abitbol V, et al. Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Presented at: The European League Against Rheumatism European Congress of Rheumatology 2019, June 12-15, 2019; Madrid, Spain. Abstract OP0227.
2. Gisondi P, Virga C, Girolomoni G. Cross-switch from CT-P13 to sb2 infliximab biosimilars in patients with chronic plaque psoriasis. Presented at: 6th Congress of Skin Inflammation and Psoriasis International Network; April 25-27, 2019; Paris, France. Abstract P049.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.